-- 独立系調査会社CFRAは、に対し、以下の調査レポートを提供しました。CFRAのアナリストは、以下のように見解をまとめています。ICEは2026年第1四半期に、前年同期の1.72ドルに対し、営業利益2.35ドルという好調な業績を達成し、市場予想を0.09ドル上回りました。純売上高は前年同期比20%増の29億8,000万ドルとなり、市場予想を1%上回りました。これは、ICEにとって2021年以来初の2桁増の四半期売上高成長であり、市場のボラティリティが高まる局面における同社の強固な回復力を示しています。地政学的不確実性が大幅な利益率拡大と記録的な収益実績を牽引した今回の四半期は、ICEのポートフォリオの強さを如実に示していると当社は考えています。取引所事業部門は、地政学的緊張の継続と世界的なサプライチェーンの混乱により、エネルギー事業の売上高が46%増の8億1,400万ドルに急増したことを筆頭に、売上高が30%増の18億ドルに急増しました。営業利益率は420ベーシスポイントも拡大し、65.2%に達しました。これは、市場の変動が激しい時期におけるICEの優れた営業レバレッジを反映したものです。同社は、5億5100万ドルの自社株買いと2億9700万ドルの配当を通じて、株主に8億4800万ドルを還元するとともに、8億6300万ドルの無制限現金を保有し、今後の成長に向けた体制を整えました。
Related Articles
Research
Research Alert: CFRA Reiterates Sell Opinion On Shares Of Hilton Worldwide Holdings Inc
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We raise our 12-month price target by $9 to $293, or 32x our 2026 EPS estimate (unchanged) and in line with shares' five-year average forward multiple. We raise our 2026 EPS estimate to $9.16 from $8.88 and lower 2027's to $10.03 from $10.20. Following Q1 results that beat expectations and included raised guidance, we maintain our 2-STARS (Sell) rating. U.S. RevPAR performance broadened from primarily luxury and upper upscale segments to include more meaningful midscale contribution, which management attributes to the return of middle- and low-income consumers. However, we note Q1 results also included ADR deceleration, particularly among luxury hotels, which historically drive significant profit contribution. HLT's Q2 EBITDA guidance of $1,015-$1,035 million being below the $1,081 million consensus suggests luxury pricing power is weakening faster than midscale volume can offset. While the broadening demand trend is positive, we believe slowing luxury tailwinds limit upside at current valuation levels.
$HLT
Research
Research Alert: CFRA Maintains Buy Rating On Shares Of Universal Health Services
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lower our 12-month price target to $200 from $243, reflecting an 8.7x multiple of our 2026 EPS estimate, below peer multiples and a discount to UHS's five-year historical forward average of 11.9x. We lower our 2026 EPS forecast to $22.95 from $23.39 and cut our 2027 view to $25.48 from $25.67. Q1 inpatient volumes were flat on a same-facility basis, with seasonal headwinds from unfavorable winter weather and a milder flu/respiratory illness period. The recent expiration of ACA EPTCs also posed challenges, as UHS estimates a near 5% drop in ACA adjusted admissions relative to Q1 2025. UHS maintained its prior forecast of a 25%-30% decline in ACA exchange volumes during the full year, which represented around 6% of the acute care business adjusted admissions in 2025 and under 5% of the acute care segment revenues. UHS anticipates a $75M pre-tax earnings hit in 2026 from these developments, unchanged from prior guidance.
$UHS
Asia
Shenghe Resources' Q1 Profit Jumps 94%, Revenue Climbs 13%
Shenghe Resources' (SHA:600392) net profit attributable to shareholders in the first quarter jumped 94% to 327.3 million yuan from 168.3 million yuan a year earlier, according to a Shanghai bourse filing on Thursday.Earnings per share rose year on year to 0.1867 yuan from 0.0960 yuan.The Chinese rare earth miner's operating revenue climbed 13% to 3.38 billion yuan from 2.99 billion yuan in the previous year.
$SHA:600392